



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: NRG-DT001 Study Chair
Meng Welliver, MD, PhD

DATE: Wednesday, August 31, 2022

RE: PROTOCOL NRG-DT001 – COHORT B CLOSURE NOTICE

Cohort B (abdomen/pelvis/retroperitoneum) of NRG-DT001, “A Phase IB Trial of Neoadjuvant AMG 232 (KRT-232) Concurrent with Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma (STS),” will permanently close to accrual at **5 PM ET Wednesday, September 7, 2022.**

NRG Oncology carefully monitors patient enrollment to studies to ensure the study can meet its goals to provide timely and meaningful results. Unfortunately, the accrual record indicates there is no feasible pathway to achieve the protocol objective in a timely manner.

All patients registered to Step 1 registration by **5 PM ET Wednesday, September 7, 2022** will be permitted to proceed to the Step 2 registration.

Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.

Please distribute this information to the appropriate personnel at participating affiliate institutions.